EPZM
$9.26
Epizyme
($.29)
(3.04%)
EPZM
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  ($0.56)
Revenue:  $6.80 Mil
Tuesday
May 25
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EPZM reports earnings?
Beat
Meet
Miss

Where is EPZM's stock price going from here?
Up
Flat
Down
Stock chart of EPZM
Analysts
Summary of analysts' recommendations for EPZM
Score
Grade
Pivots
Resistance
$10.09
$9.89
$9.57

$9.37

Support
$9.06
$8.86
$8.54
Tweet
Growth
Description
Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.
Peers
InterCeptVertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsZoetisUltragenyx PharmaceuticalBristol-Myers SquibbPfizerMerck & Co.Johnson & Johnson